

Basic Search

[Advanced Search](#) [Search Preferences](#)

keyword:propylene AND keyword:glycol AND (polymor

Search

☒ Journal sources ☒ Preferred Web sources ☒ Other Web sources ☐ Exact phrase

Searched for:: :All of the words:keyword:propylene AND keyword:glycol AND (polymorph*)

Found:: :**30 total** | **7 journal results** | **21 preferred web results** | **2 other web results**

Sort by:: :**relevance** | [date](#)

Save checked results

Email checked results

Export checked results

Refine your search using these key words found in the results: **solubility**

Or refine using:

All of the words

Refine

- ☐ 1. [Synthesis of S-\(\[¹⁸F\]fluoromethyl\)-\(+\)-McN5652 as a potential PET radioligand for the serotonin transporter](#)
Zessin, J. / Eskola, O. / Brust, P. / Bergman, J. / Steinbach, J. / Lehtikoinen, P. / Solin, O. / Johannsen, B., *Nuclear Medicine and Biology*, Oct 2001
The present study describes the synthesis of the [¹⁸F]fluoromethyl analogue of (+)-McN5652 ([¹⁸F]FMe-McN) as a new potential tracer for the serotonin transporter. In vitro binding studies have shown that FMe-McN displays only...

Published journal article available from  **ScienceDirect**

[view all 6 results from ScienceDirect](#)
[similar results](#)

- ☐ 2. [Solubility and stability characterization of zileuton in a ternary solvent system](#)
Trivedi, J.S. / Porter, W.R. / Fort, J.J., *European Journal of Pharmaceutical Sciences*, Mar 1996
...Brooks et al., 1990). It strongly inhibits S-lipoxygenase activity in rat basophilic leukemia-1 cells and in rat and human **polymorphonuclear** leukocytes. Zileuton is now approved in the United States for use in asthma. Recent findings in patients with ulcerative...





Published journal article available from  **ScienceDirect**

[view all 6 results from ScienceDirect](#)
[similar results](#)

- ☐ 3. [In vitro effect of additives in benzodiazepine solutions on the superoxide anion-generating system in polymorphonuclear leucocytes.](#)
Morisaki, H / Tanaka, T / Ishimura, Y / Takeda, J / Sekiguchi, H / Nagano, M, *British journal of anaesthesia*, Jan 1991
...pure preparations were compared using porcine and human **polymorphonuclear** leucocytes in vitro, the solutions were found to be more...appreciable effect on the O₂(-)-generating system in **polymorphonuclear** leucocytes of patients.

MEDLINE/PubMed Citation on PubMed

[similar results](#)

- ☐ 4. [Propylene glycol as a drug solvent in pharmacologic studies](#)
Zaroslinski, J.F. / Browne, R.K. / Possley, L.H., *Toxicology and Applied Pharmacology*, Aug 1971
...PG is used as the injection solvent since they observed a marked decrease in clotting time, increases in platelet and **polymorphonuclear** leukocyte counts as well as a decrease in lymphocytes following its administration. The present communication reports...
Published journal article available from  ScienceDirect
[view all 6 results from ScienceDirect](#)
[similar results](#)
- ☐ 5. [Influence of solvent composition on the solubilities and solid-state properties of the sodium salts of some drugs](#)
Rubino, J.T. / Thomas, E., *International Journal of Pharmaceutics*, Nov 1990
...Methylxanthines in mixed solvents. *J. Pharm. Sci.*, 70 (1981) 1115-1120. Pfeiffer, R.R., Yang, K.S. and Tucker, M.A., Crystal pseudo- **polymorphism** of cephaloglycin and cephalexin. *J. Pharm. Sci.*, 59 (1970) 1809-1814. Rubino, J.T., Solubilities and solid state properties...
Published journal article available from  ScienceDirect
[view all 6 results from ScienceDirect](#)
[similar results](#)
- ☐ 6. [Hematologic effects following the intravenous injection of propylene glycol in the rabbit](#)
Brittain, R.T. / D'Arcy, P.F., *Toxicology and Applied Pharmacology*, Nov 1962
...increase in the number of circulating **polymorphs** at 3 and 6 hours after the injection...glycol however, by 24 hours the level of **polymorphs** had returned to preinjection levels...there was an increase in circulating **polymorphs** and a corresponding decrease in lymphocytes...
Published journal article available from  ScienceDirect
[view all 6 results from ScienceDirect](#)
[similar results](#)
- ☐ 7. [Acute and chronic toxicity of rubratoxin B](#)
Wogan, G.N. / Edwards, G.S. / Newberne, P.M., *Toxicology and Applied Pharmacology*, Aug 1971
...and spread peripherally in the lobule. In mice, hemorrhagic and necrotic changes were accompanied by the presence of **polymorphonuclear** leukocytes in the necrotic zones. RUBRATOXIN B TOXICITY 715 Cats showed remarkably severe reactions to rubratoxin B. In...
Published journal article available from  ScienceDirect
[view all 6 results from ScienceDirect](#)
[similar results](#)

 **fast**

[Downloads](#) | [Subscribe to News Updates](#) | [User Feedback](#) | [Advertising](#)
[Tell A Friend](#) | [Terms Of Service](#) | [Privacy Policy](#) | [Legal](#)

Powered by FAST © Elsevier 2007

Searched for:: :All of the words:keyword:olanzapine AND (polymorph*)





Found:: :378 total | [103 journal results](#) | [139 preferred web results](#) | [136 other web results](#)

Sort by:: :relevance | [date](#)

[Save checked results](#)

[Email checked results](#)

[Export checked results](#)

- ☐ 1. [Crystal structure of olanzapine and its solvates. Part 3. Two and three-component solvates with water, ethanol,...](#)
Wawrzycka-Gorczyca, I. / Borowski, P. / Osypiuk-Tomasik, J. / Mazur, L. / Koziol, A.E., *Journal of Molecular Structure*, Mar 2007
...be complicated by its ability to form **polymorphs**, hydrates and other solvates. Determination...pharmaceutical industry. So far, six **polymorphic** unsolvated crystalline forms of1have...been also claimed[12]. The most stable **polymorph** II crystallizes from anhydrous solvents...
Published journal article available from  **ScienceDirect**
[view all 77 results from ScienceDirect](#)
[similar results](#)
- ☐ 2. [Quantification of olanzapine polymorphs using powder X-ray diffraction technique](#)
Tiwari, M. / Chawla, G. / Bansal, A.K., *Journal of Pharmaceutical and Biomedical Analysis*, Feb 2007
...and smoothened PXRD patterns of OLZ **polymorphs** (a) form I, (b) form II, "*" shows the...Calibration curve for determination of OLZ **polymorphic** form I in form II by PXRD. Fig. 5 Correlation...D.) 5.2 Quantification of olanzapine **polymorphs** using powder X-ray diffraction technique...
Published journal article available from  **ScienceDirect**
[view all 77 results from ScienceDirect](#)
[similar results](#)
- ☐ 3. [Solid state characterization of olanzapine polymorphs using vibrational spectroscopy.](#)
Ayala, A P / Siesler, H W / Boese, R / Hoffmann, G G / Polla, G I / Vega, D R, *International journal of pharmaceutics*, Dec 2006
...near infrared investigations of two **polymorphs** of olanzapine are presented, establishing...the conformers corresponding to each **polymorph** and to assign the vibrational bands...relationship between the investigated **polymorphs**.
MEDLINE/PubMed Citation on  **PubMed**
[view all 17 results from MEDLINE/PubMed](#)
[similar results](#)
- ☐ 4. [Atypical antipsychotics in bipolar depression: Neurobiological basis and clinical implications](#)
Brugue, E. / Vieta, E., *Progress in Neuropsychopharmacology & Biological Psychiatry*, Jan 2007
The use of atypical antipsychotics is rapidly expanding in the management of bipolar disorder. This therapeutic class appears to have benefits across the spectrum of moods found in bipolar disorder, and a re-examination of the monoamine...
Published journal article available from  **ScienceDirect**
[view all 77 results from ScienceDirect](#)
[similar results](#)
- ☐ 5. [Subject index of volume 30](#)
Progress in Neuropsychopharmacology & Biological Psychiatry, Dec 2006
...nin 30/4, 694 Adverse effects 5-HTT **polymorphisms** Plasma concentrations Sertra-line...Mirtazapine 30/7, 1196 Allele-variant **polymorphisms** Anxiety disorders Combat-related PTSD...338 Anxiety disorders Allele-variant **polymorphisms** Combat-related

PTSD DSM-V Large-scale...

Published journal article available from  **ScienceDirect**

[view all 77 results from ScienceDirect](#)

[similar results](#)

- ☐ 6. [The relationship between P-glycoprotein \(PGP\) polymorphisms and response to olanzapine treatment in schizophrenia.](#)
Lin, Ying-Chi / Ellingrod, Vicki L / Bishop, Jeffrey R / Miller, Del D, *Therapeutic drug monitoring*, Oct 2006
P-glycoprotein (PGP) is a **polymorphic** efflux transporter located on...relationship between three common PGP **polymorphisms** (C1236T, G2677TA, and C3435T...PGP T allele at any of these **polymorphisms** would be expected to have greater...

MEDLINE/PubMed Citation on  **PubMed**

[view all 17 results from MEDLINE/PubMed](#)

[similar results](#)

- ☐ 7. [Solid state characterization of olanzapine polymorphs using vibrational spectroscopy](#)
Ayala, A.P. / Siesler, H.W. / Boese, R. / Hoffmann, G.G. / Polla, G.I. / Vega, D.R., *International Journal of Pharmaceutics*, Dec 2006
...Raman and (b) infrared spectra of the **polymorphs** of olanzapine above 2500cm⁻¹. Fig. 5 (a) Raman and (b) infrared spectra of the **polymorphs** of olanzapine below 1700cm⁻¹. Fig. 6...Raman and (b) infrared spectra of the **polymorphs** of olanzapine in thenu(CC) andnu(CN...

Published journal article available from  **ScienceDirect**

[view all 77 results from ScienceDirect](#)

[similar results](#)

- ☐ 8. [Prefrontal dysfunction in schizophrenia controlling for COMT Val¹⁵⁸Met genotype and working memory performance](#)
Bertolino, A. / Caforio, G. / Petruzzella, V. / Latorre, V. / Rubino, V. / Dimalta, S. / Torracio, A. / (...) / Mattay, V.S., *Psychiatry Research: Neuroimaging*, Oct 2006
...al., 2005 B.C. Ho T.H. Wassink D.S. O'Leary V.C. Sheffield N.C. Andreasen Catechol-O-methyl transferase Val(158)Met gene **polymorphism** in schizophrenia: working memory, frontal lobe MRI morphology and frontal cerebral blood flow *Molecular Psychiatry* 10 2005...

Published journal article available from  **ScienceDirect**

[view all 77 results from ScienceDirect](#)

[similar results](#)

- ☐ 9. [The use of intramuscular benzodiazepines and antipsychotic agents in the treatment of acute agitation or violence in the...](#)
Rund, D.A. / Ewing, J.D. / Mitzel, K. / Votolato, N., *Journal of Emergency Medicine*, Oct 2006
...training Obesity Sleeping Hypothyroidism Alcoholism Hypoglycemia Advanced age Bradycardia Hypokalemia/hypomagnesemia Genetic **polymorphisms** of gene coding cardiac ion channels or enzymes in liver metabolizing drugs Congestive heart failure Cardiac dysrhythmias...

Published journal article available from  **ScienceDirect**

[view all 77 results from ScienceDirect](#)

[similar results](#)

- ☐ 10. [Serum creatine kinase levels in chronic psychosis patients - a comparison between atypical and conventional...](#)
Melkersson, K., *Progress in Neuropsychopharmacology & Biological Psychiatry*, Sep 2006
...al., 1991 M.L. Dahl B. Ekqvist J. Widen L. Bertilsson Disposition of the neuroleptic zuclopenthixol cosegregates with the **polymorphic** hydroxylation of debrisoquine in

humans Acta Psychiatr Scand 84 1991 99 100 Devarajan and Dursun, 2000 S. Devarajan S.M...

Published journal article available from  **ScienceDirect**

[view all 77 results from ScienceDirect](#)

[similar results](#)

11. [Effects of olanzapine on aggressiveness in heroin dependent patients](#)
Gerra, G. / Di Petta, G. / D'Amore, A. / Iannotta, P. / Bardicchia, F. / Falorni, F. / Coacci, A. / (...) / Lucchini, A., *Progress in Neuropsychopharmacology & Biological Psychiatry*, Sep 2006

This study compared the anti-aggressiveness effects of the atypical anti-psychotic olanzapine with that of selective serotonin reuptake inhibitors (SSRI) and benzodiazepines (BZD) among patients with heroin dependence submitted to...

Published journal article available from  **ScienceDirect**

[view all 77 results from ScienceDirect](#)

[similar results](#)

12. [Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a community mental health centre](#)

Tarricone, Ilaria / Casoria, Michela / Gozzi, Beatrice Ferrari / Grieco, Daniela / Menchetti, Marco / Serretti, Alessandro / Ujkaj, Manjola / (...) / Berardi, Domenico, *BMC Psychiatry*, Mar 2006

Second generation antipsychotics (SGA) have demonstrated several advantages over first generation antipsychotics (FGA) in terms of positive, negative, cognitive, and affective symptoms and a lower propensity for extrapyramidal side effects. Despite these ...

Published journal article available from  **BioMed Central**

[view all 4 results from BioMed Central](#)

[similar results](#)

13. [Weight gain associated with the alpha2a-adrenergic receptor -1,291 C/G polymorphism and olanzapine treatment.](#)

Park, Young-Min / Chung, Young-Cho / Lee, Seung-Hwan / Lee, Kang-Joon / Kim, Hyun / Byun, Young-Chan / Lim, Se-Won / (...) / Lee, Heon-Jeong, *American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics*, Jun 2006

...2a)-adrenergic receptor -1,291 C/G **polymorphism** and olanzapine-induced weight gain...treatment. Genotyping for the -1291 C/G **polymorphism** was performed on all participants...relationship between the -1291 C/G **polymorphism** of the alpha(2a)-adrenergic receptor...

MEDLINE/PubMed Citation on  **PubMed**

[view all 17 results from MEDLINE/PubMed](#)

[similar results](#)

14. [The effect of olanzapine on craving and alcohol consumption.](#)

Hutchison, Kent E / Ray, Lara / Sandman, Erica / Rutter, Marie-Christine / Peters, Annie / Davidson, Dena / Swift, Robert, *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*, Jun 2006

...of alcohol is greater among individuals with the seven-repeat allele of the DRD4 variable number of tandem repeats (VNTR) **polymorphism**, and that the effect of olanzapine (a D2/D4 antagonist) is more pronounced among individuals with this allele. The present...

MEDLINE/PubMed Citation on  **PubMed**

[view all 17 results from MEDLINE/PubMed](#)

[similar results](#)

15. Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia.
Bishop, Jeffrey R / Ellingrod, Vicki L / Moline, Jessica / Miller, Del, Medical science monitor : international medical journal of experimental and clinical research, Feb 2006
...second messenger G-Protein Beta3 Subunit Gene (GNB3) C825T **polymorphism** and olanzapine response and weight gain treatment. MATERIAL...results showed no statistical relationship between the C825T **polymorphism** and olanzapine response or weight gain. Numerical differences...

MEDLINE/PubMed Citation on PubMed

[view all 17 results from MEDLINE/PubMed](#)
[similar results](#)

16. A PROCESS FOR MAKING OLANZAPINE IN A POLYMORPH FORM I
KELTJENS, Rolf, EUROPEAN PATENT APPLICATION, Nov 2006
Full text available at patent office. For more in-depth searching go to LexisNexis®
[view all 139 results from Patent Offices](#)
[similar results](#)

17. P.3.c.055 Dopamine D3 receptor polymorphism associated with amisulpride response on negative symptoms of schizophrenia
Huang, S.Y., European Neuropsychopharmacology, Jan 2006
S426 P.3.cPsychoticdisordersandantipsychotics~Antipsychotics(clinical) schizophrenia, schizophreniform disorder, or schizoaffective disorder randomized to olanzapine (2.5 to 20 mg/d), quetiapine (100 to 800 mg/d), or risperidone (0.5 to 4 mg/d).
Published journal article available from ScienceDirect
[view all 77 results from ScienceDirect](#)
[similar results](#)

18. P.3.c.035 SNAP-25 gene polymorphisms and weight gain in schizophrenic patients treated with atypical antipsychotics
Musil, R.L. / Spellmann, I. / Riedel, M. / Douhet, A. / Dehning, S. / Maino, K. / Zill, P. / (...) / Bondy, B., European Neuropsychopharmacology, Jan 2006
P.3.cPsychoticdisordersandantipsychotics~Antipsychotics(clinical) S415 was within recommended limits for all medications. The reduction in antipsychotic dose between that used in schizophrenia, and that used in mood disorder ranged from 16% (clozapine) to 59% (risperidone). No.
Published journal article available from ScienceDirect
[view all 77 results from ScienceDirect](#)
[similar results](#)

19. P.3.a.027 In fluences of polymorphisms of beta adrenergic receptors in the psychopharmacological treatment of...
Spellmann, I. / Riedel, M. / Musil, R.L. / Douhet, A. / Dehning, S. / Zill, P. / Muller, N. / (...) / Bondy, B., European Neuropsychopharmacology, Jan 2006
S378 P.3.aPsychoticdisordersandantipsychotics~Psychoticdisorders(clinical) both groups, with 143.5 (DT 68) days for quetiapine and 144.1 (DT 62.5) days for olanzapine.
Published journal article available from ScienceDirect
[view all 77 results from ScienceDirect](#)
[similar results](#)

20. S.14.04 CATIE trial results
Lieberman, J.A. / Stroup, T.S. / McEvoy, J.P. / Swartz, M.S. / Keefe, R. / Perkins, D.O. / Davis, S. / (...) / Hsiao, J., European Neuropsychopharmacology, Jan 2006
...neuronal populations affected in these diseases. S.14 New clinical research in

schizophrenia S.14.01 Regional brain metabolism (18FDG PET) and **polymorphisms** for candidate genes in schizophrenia: from SNPs to phenotypes J. Horacek ° , F. Spaniel, T. Novak, M. Kopecek, P. Mohr...

Published journal article available from  ScienceDirect

[view all 77 results from ScienceDirect](#)
[similar results](#)